According to Redhill Biopharma's latest financial reports the company's current revenue (TTM) is $35.74 M. In 2022 the company made a revenue of $61.8 M a decrease over the years 2021 revenue that were of $85.75 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $35.74 M | -42.16% |
2022 | $61.8 M | -27.94% |
2021 | $85.75 M | 33.25% |
2020 | $64.35 M | 923.03% |
2019 | $6.29 M | -24.75% |
2018 | $8.36 M | 108.63% |
2017 | $4 M | 3867.33% |
2016 | $0.1 M | 3266.67% |
2015 | $0 M | -99.96% |
2014 | $7.01 M | 58350% |
2013 | $0.01 M | -25% |
2012 | $0.01 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Sanofi SNY | $50.51 B | 141,216.39% | ๐ซ๐ท France |
Merck MRK | $61.40 B | 171,677.87% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $38.54 B | 107,729.00% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | $16.00 B | 44,669.90% | ๐ฎ๐ฑ Israel |
Taro Pharmaceutical TARO | $0.61 B | 1,608.85% | ๐ฎ๐ฑ Israel |